

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Potti, Anil	POSITION TITLE Assistant Professor of Medicine Division of Hematology/Oncology
eRA COMMONS USER NAME anil.potti	

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Christian Medical College, Vellore, India	M.B., B.S.	1989-1995	Medicine
Univ. North Dakota School of Medicine	Residency	1997-2000	Internal Medicine
Univ. North Dakota School of Medicine	Chief	2000-2001	Internal Medicine
Duke University Medical Center, Durham, NC	Fellowship	2003	Hematology/Oncology

### A. Positions and Honors:

- 1995 – 1996            Research Fellowship at Queensland Research Institute, Australia.  
   Studying the cardiac effects of malaria and *beta-thalassemia/HgbE* disease in south-east  
   Asians (Mentor: Dr. Gordon McLaren).
- 2003 – present            Clinical Research Fellow – Duke University Medical Center  
   (Mentors: Dr. Joseph Nevins and Dr. Michael Kelley)

### Honors:

- 1995 Rhodes Scholar (Australia).  
1997 Resident Teacher of the Year – UND School of Medicine.  
1998 American Society of Clinical Oncology (ASCO) Merit Award.  
1998 Young Investigator Award - AFMR/CSCR.  
1998 Research Competition Winner at the Annual ACCP Scientific Meeting.  
1999 Alpha-Omega-Alpha (AOA) Honor Society Membership.  
2000 UND Academic & Teaching Excellence Award.  
2001 Cure for Lymphoma & Lymphoma Research Foundation Award.  
2001 Young Investigator Award - Central Society of Clinical Research (CSCR)  
2002 Golden Apple Award (teaching award from medical students).  
2003 Leonard P. Tow Humanism in Medicine Award.  
2003 Golden Apple Award (teaching award from medical students).  
2003 Frank N. Low Prize in Clinical Research.  
2004 Claus Strohlein Research Award.  
2004 American Society of Hematology (ASH) CRTI Scholar.  
2005 ASCO/Aventis fellows Merit Award.  
2005 Duke Scholar in Genomic Medicine.  
2006 Robert Silber research Prize.  
2006 Robert and Barbara Bell Post Doctoral Research Excellence Award.  
2006 AACR-Cancer Prevention Foundation Award for Excellence in Translational Research.  
2006 NIH Career Development (K) Award.

**B. Selected peer-reviewed publications:** (in chronological order)

1. Pandita D, Steen P, **Potti, A.** Risk factors for deep venous thrombosis of the upper extremities. *Ann Inter Med.* 1997; 127(12):1129-32.
2. **Potti A,** Abdel-Raheem M, Levitt R, Schell DA, Mehdi SA. Intramedullary spinal cord metastases (ISCM) and non-small cell lung carcinoma (NSCLC): clinical patterns, diagnosis and therapeutic considerations. *Lung Cancer.* 2001;31(2-3):319-23.
3. **Potti A,** Schell DA. Acute adrenal insufficiency due to metastatic lung cancer. *J Clin Oncol.* 2001;19(17):3780-2.
4. **Potti A,** Ganti AK, Koch M, Mehdi SA, Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. *Lung Cancer.* 2001;34(2):227-32.
5. Gill N, Malik A, **Potti A,** Talukdar R, Saberi A, Mehdi SA. HER-2/neu overexpression in colonic malignancies. *Gastroenterology.* 2002;122(1):248-9.
6. Abdel-Raheem MM, **Potti A,** Becker WK, Saberi A, Scilley BS, Mehdi SA. Late adrenal metastasis in operable non-small-cell lung carcinoma. *Am J Clin Oncol.* 2002;25(1):81-3. Review.
7. **Potti A,** Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, Levitt R, Mehdi SA. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. *Lung Cancer.* 2002;36(3):257-61.
8. Foster H, Knox S, Ganti AK, Hebert BJ, Koch M, Tendulkar K, Levitt R, **Potti A.** HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. *Am J Clin Oncol.* 2003;26(2):188-91.
9. **Potti A,** Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. *Ann Oncol.* 2003;14(6):894-7.
10. **Potti A,** Ganti AK, Sholes K, Langness E, Koka V, Horvarth L, Koch M. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. *Clin Cancer Res.* 2003;9(13):4872-6.
11. **Potti A,** Mariani P, Saeed M, Smego RA Jr. Residents as researchers: expectations, requirements, and productivity. *Am J Med.* 2003;115(6):510-14.
12. **Potti A,** Hille RC, Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. *J Carcinog.* 2003;2(1):8.
13. **Potti A,** Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, Kargas S. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. *J Cancer Res Clin Oncol.* 2003;130(1):52-6.
14. **Potti A,** Rusconi CP, Sullenger BA, Ortel TL. Regulatable aptamers in medicine. *Expert Opin Biol Ther.* 2004; 4(10):1641-7.
15. **Potti A.** HER-2/neu overexpression in colorectal carcinoma. *Gastroenterology.* 2004; 122(1):248-9.
16. **Potti A,** Panwalkar A, Langness E, Sholes K, Tendulkar K, Chittajalu S, Koch M. Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas. *J Clin Oncol.* 2004 Oct;27(5):452-6
17. **Potti A,** Moazzam N, Langness E, Sholes K, Tendulkar K, Koch M, Kargas S. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. *Cancer Res* 2004;130(2):80-6.
18. Chen G, Shukeir N, **Potti A,** Sircar K, Aprikian A, Goltzman D, Rabbani SA. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. *Cancer.* 2004 Sep 15;101(6):1345-56.
19. **Potti A,** George DJ. Tyrosine kinase inhibitors in renal cell carcinoma. *Clin Cancer Res.* 2004 Sep 15;10 (182) :6371-6.

20. **Potti A**, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, Mehdi SA, Levitt R. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. *Cancer Invest.* 2004;22(4):537-44.
21. Patel P, Henry LL, Ganti AK, **Potti A**. Clinical course of lung cancer in patients with chronic kidney disease. *Lung Cancer.* 2004;43(3):297-300.
22. **Potti A**, Ganti AK, Tuchman SA, Sholes K, Langness E, Koka V, Koch M. HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). *J Carcinog.* 2005;4(1):8
23. Ganti AK, **Potti A**. Epidermal growth factor inhibition in solid tumours. *Expert Opin Biol Ther.* 2005 Sep;5(9):1165-1174.
24. **Potti A**, Bild A, Dressman H, Lewis DA, Nevins JR, Ortel TL. Gene expression patterns predict phenotypes of cancer mediated thrombosis. *Blood*, Nov 2005. epub..
25. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar K, **Potti A**. Hormone replacement therapy is associated with decreased survival in women with lung cancer. *J Clin Oncol.* Dec 2005 (epub).
26. Bild A, Yao G, Chang JT, **Potti A**, Chasse D, Harpole D, Lancaster JL, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Signatures of oncogenic pathway deregulation in human cancers as a guide to targeted therapeutics. *Nature.* Nov 2005 (epub).
27. Lancaster JM, Dressman HK, Chan G, Zhai J, Bild A, Cragun J<sup>4</sup>, Sayer R, Clarke J, Whitaker RS, Gray RS, Marks J, Ginsburg GS, **Potti A**, West M, Berchuck A, Nevins JR. An integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. *J Clin Oncol* (invited revisions submitted).
28. **Potti A**, Dressman HK, Bild A, Riedel R, Lancaster J, Berchuk A, Kelley M, Ginsberg G, Nevins JR, Febbo PG. A genomic approach to combinatorial therapeutics in solid tumors. *Nature Medicine* (invited revisions submitted).
29. **Potti A**, Mukherjee S, Petersen R, Dressman HK, Bild A, Kratzke R, Watson M, Kelley MJ, Ginsburg G, West M, Harpole D, Nevins JR. A Genomic Strategy to Refine Prognosis and Therapeutic Decision for Adjuvant Therapy in Non-Small Cell Lung Carcinoma. *New Engl J Med* (accepted for publication).